Verica Aleksic Sabo

Dr. Verica Aleksic Sabo

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Microbiological Research
Verified
Journal Article
Closed access
Verica Aleksic SaboVerica Aleksic Sabo
Verica Aleksic Sabo
PKPetar Knezevic
Petar Knezevic

1 June 2019 in Industrial Crops and Products
Verified
Journal Article
Closed access
Verica Aleksic SaboVerica Aleksic Sabo
Verica Aleksic Sabo
PKPetar Knezevic
Petar Knezevic

1 February 2016 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
PKPetar Knezevic
Petar Knezevic
Verica Aleksic SaboVerica Aleksic Sabo
Verica Aleksic Sabo
NSNatasa Simin
Natasa Simin
ESEmilija Svirčev
Emilija Svirčev
APAleksandra Petrovic
Aleksandra Petrovic
NMNeda Mimica-Dukic
Neda Mimica-Dukic

1 January 2013 in Research in Microbiology
Verified
Journal Article
Closed access
PKPetar Knezevic
Petar Knezevic
SCSanja Curcin
Sanja Curcin
Verica Aleksic SaboVerica Aleksic Sabo
Verica Aleksic Sabo
MPMilivoje Petrusic
Milivoje Petrusic
LVLjiljana Vlaski
Ljiljana Vlaski

1 October 2014 in Phytomedicine
Verified
Journal Article
Closed access
Verica Aleksic SaboVerica Aleksic Sabo
Verica Aleksic Sabo
NMNeda Mimica-Dukic
Neda Mimica-Dukic
NSNatasa Simin
Natasa Simin
NNNatasa Stankovic Nedeljkovic
Natasa Stankovic Nedeljkovic
PKPetar Knezevic
Petar Knezevic

14 July 2022 in Viruses
Verified
Journal Article
Open access
PDF file
INIsidora Nikolic
Isidora Nikolic
DVDarija Vukovic
Darija Vukovic
Damir GavricDamir Gavric
Damir Gavric
JCJelena Cvetanović
Jelena Cvetanović
Verica Aleksic SaboVerica Aleksic Sabo
Verica Aleksic Sabo
PKPetar Knezevic
Petar Knezevic
Phage-antibiotic synergy is a promising therapeutic strategy, but there is no reliable method for synergism estimation. Although the time-kill curve assay is a gold standard, the method is not appropriate for fast and extensive screening of the synergy. The aim is to optimize the checkerboard method to determine phage-chemical agent interactions, to check its applicability by the time-kill curve method, and to examine whether the synergy can be obtained with both simultaneous and successive applications of these agents. In addition, the aim is to determine interactions of the Pseudomonas phage JG024 with ciprofloxacin, gentamicin, or ceftriaxone, as well as the Staphylococcus phage MSA6 and SES43300 with ciprofloxacin, gentamicin, and oxacillin. The results show that the optimized checkerboard method is reliable and that results correspond to those obtained by the time-kill curve. The synergy is detected with the phage JG024 and ciprofloxacin or ceftriaxone against Pseudomonas aeruginosa, and the phage SES43300 with ciprofloxacin against MRSA. The synergy was obtained after simultaneous applications, and in the case of P. aeruginosa, after application of the second agent with delay of one hour, indicating that simultaneous application is the best mode of synergy exploitation for therapy. The checkerboard method can be used for thorough clinical studies on synergy and in the future for personalized therapy when infections are caused by multiple resistant bacteria.